1. The role of gemtuzumab ozogamicin in combination chemotherapy regimens for primary resistant or relapsed acute myeloid leukemia

   • Hien K. Duong
   • Matt Kalaycio

   Clinical Trials Report 22 March 2009 Pages: 55 - 56

2. Predicting the response of CML patients to tyrosine kinase inhibitor therapy

   • Deborah L. White
   • Timothy P. Hughes

   OriginalPaper 22 March 2009 Pages: 59 - 65

3. Chronic myelogenous leukemia stem cells: What’s new?

   • Mhairi Copland

   OriginalPaper 22 March 2009 Pages: 66 - 73

4. Clinical implications of c-Kit mutations in acute myelogenous leukemia

   • Muriel Malaise
   • Daniel Steinbach
   • Selim Corbacioglu

   OriginalPaper 22 March 2009 Pages: 77 - 82

5. MicroRNA expression in acute myeloid leukemia

   • Guido Marcucci
   • Michael D. Radmacher
   • Clara D. Bloomfield

   OriginalPaper 22 March 2009 Pages: 83 - 88

6. Treatment of immunoglobulin light chain amyloidosis

   • Morie A. Gertz
   • Steven R. Zeldenrust

   OriginalPaper 22 March 2009 Pages: 91 - 98

7. Treatment of relapsed and refractory myeloma

   • Jonathan Kaufman
   • Charise Gleason
   • Sagar Lonial

   OriginalPaper 22 March 2009 Pages: 99 - 107

8. The role of bisphosphonates in multiple myeloma

   • Jessica Levy
   • G. David Roodman

   OriginalPaper 22 March 2009 Pages: 108 - 112